Search: WFRF:(Nemtsas P) > Blood Pressure Lowe...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06833naa a2201249 4500 | |
001 | oai:gup.ub.gu.se/284857 | |
003 | SwePub | |
008 | 240528s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2848572 URI |
024 | 7 | a https://doi.org/10.1161/jaha.119.0119382 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a de Heus, R. A. A.4 aut |
245 | 1 0 | a Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2019 |
520 | a Background-Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from hypertension trials, evidence regarding safety of treatment is lacking. This secondary analysis of a randomized controlled trial assessed whether antihypertensive treatment increases the prevalence of orthostatic hypotension (OH) in patients with Alzheimer disease. Methods and Results-Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence of OH (blood pressure drop >= 20/>= 10 mm Hg after 1 minute of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up visits. Mean age of the study population was 72.2 +/- 8.2 years and mean Mini-Mental State Examination score was 20.4 +/- 3.8. Baseline blood pressure was 137.8 +/- 14.0/77.0 +/- 8.6 mm Hg. Grade I hypertension was present in 53.4% (n=255). After 13 weeks, blood pressure had fallen by -7.8/-3.9 mm Hg for nilvadipine and by -0.4/-0.8 mm Hg for placebo (P<0.001). Across the 78-week intervention period, there was no difference between groups in the proportion of patients with OH at a study visit (odds ratio [95% CI] 1.1 [0.8-1.5], P 0.62), nor in the proportion of visits where a patient met criteria for OH, corrected for number of visits (7.7 +/- 13.8% versus 7.3 +/- 11.6%). OH-related adverse events were not more often reported in the intervention group compared with placebo. Results were similar for those with baseline hypertension. Conclusions-This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a adverse drug event | |
653 | a Alzheimer disease | |
653 | a antihypertensive agent | |
653 | a calcium channel blocker | |
653 | a orthostatic | |
653 | a antihypertensive treatment | |
653 | a cognitive impairment | |
653 | a consensus statement | |
653 | a cardiovascular risk | |
653 | a european-society | |
653 | a hypertension | |
653 | a association | |
653 | a management | |
653 | a older | |
653 | a dementia | |
700 | 1 | a Donders, R.4 aut |
700 | 1 | a Santoso, A. M. M.4 aut |
700 | 1 | a Rikkert, Mgmo4 aut |
700 | 1 | a Lawlor, B. A.4 aut |
700 | 1 | a Claassen, Jahr4 aut |
700 | 1 | a Segurado, R.4 aut |
700 | 1 | a Kennelly, S.4 aut |
700 | 1 | a Howard, R.4 aut |
700 | 1 | a Pasquier, F.4 aut |
700 | 1 | a Börjesson-Hanson, Anne,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xborja |
700 | 1 | a Tsolaki, M.4 aut |
700 | 1 | a Lucca, U.4 aut |
700 | 1 | a Molloy, D. W.4 aut |
700 | 1 | a Coen, R.4 aut |
700 | 1 | a Riepe, M. W.4 aut |
700 | 1 | a Kalman, J.4 aut |
700 | 1 | a Kenny, R. A.4 aut |
700 | 1 | a Cregg, F.4 aut |
700 | 1 | a O'Dwyer, S.4 aut |
700 | 1 | a Walsh, C.4 aut |
700 | 1 | a Adams, J.4 aut |
700 | 1 | a Banzi, R.4 aut |
700 | 1 | a Breuilh, L.4 aut |
700 | 1 | a Daly, L.4 aut |
700 | 1 | a Hendrix, S.4 aut |
700 | 1 | a Aisen, P.4 aut |
700 | 1 | a Gaynor, S.4 aut |
700 | 1 | a Sheikhi, A.4 aut |
700 | 1 | a Taekema, D. G.4 aut |
700 | 1 | a Verhey, F. R.4 aut |
700 | 1 | a Nemni, R.4 aut |
700 | 1 | a Nobili, F.4 aut |
700 | 1 | a Franceschi, M.4 aut |
700 | 1 | a Zanetti, O.4 aut |
700 | 1 | a Konsta, A.4 aut |
700 | 1 | a Anastasios, O.4 aut |
700 | 1 | a Nenopoulou, S.4 aut |
700 | 1 | a Tsolaki-Tagarak, F.4 aut |
700 | 1 | a Pakaski, M.4 aut |
700 | 1 | a Dereeper, O.4 aut |
700 | 1 | a de la Sayette, V.4 aut |
700 | 1 | a Senechal, O.4 aut |
700 | 1 | a Lavenu, I.4 aut |
700 | 1 | a Devendeville, A.4 aut |
700 | 1 | a Calais, G.4 aut |
700 | 1 | a Crawford, F.4 aut |
700 | 1 | a Mullan, M.4 aut |
700 | 1 | a Aalten, P.4 aut |
700 | 1 | a Berglund, M. A.4 aut |
700 | 1 | a de Jong, D. L. K.4 aut |
700 | 1 | a Godefroy, O.4 aut |
700 | 1 | a Hutchinso, S.4 aut |
700 | 1 | a Loannou, A.4 aut |
700 | 1 | a Jonsson, Michael,d 1955u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xjonmi |
700 | 1 | a Kent, A.4 aut |
700 | 1 | a Kern, Jürgenu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xkerju |
700 | 1 | a Nemtsas, P.4 aut |
700 | 1 | a Panidou, M. K.4 aut |
700 | 1 | a Abdullah, L.4 aut |
700 | 1 | a Paris, D.4 aut |
700 | 1 | a van Spijker, G. J.4 aut |
700 | 1 | a Spiliotou, M.4 aut |
700 | 1 | a Thomoglou, G.4 aut |
700 | 1 | a Wallin, Anders,d 1950u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xwaand |
700 | 1 | a Frisoni, G.4 aut |
700 | 1 | a Nilvad Study, Grp4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Journal of the American Heart Associationd : Ovid Technologies (Wolters Kluwer Health)g 8:10q 8:10x 2047-9980 |
856 | 4 | u https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.011938 |
856 | 4 8 | u https://gup.ub.gu.se/publication/284857 |
856 | 4 8 | u https://doi.org/10.1161/jaha.119.011938 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view